Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Post by Konderoon Sep 26, 2012 10:23pm
281 Views
Post# 20418534

About Previstage...

About Previstage...

Diagnocure failed to sell the test by its own; its partner , Lab 21 in the United Kingdom, failed too in 2009; finally, Signal Genetics seems to follow the same rut. Those failures have in common the fact that none of them was preceded by a positive clinical study strongly validated by a second one. Cur wants to correct that deficiency with the Vitar study ( part l and part ll ).

Because that's what colorectal cancer specialists are expecting: a test with a high pronostic value , as guidance for different adapted therapies: chemotherapy, radiotherapy etc. They want indisputable results coming from scientific studies.

Fantomatus

<< Previous
Bullboard Posts
Next >>